Addiction-associated behaviors such as drug craving and relapse are hypothesized to result from synaptic changes that persist long after withdrawal and are renormalized by drug reinstatement, although such chronic synaptic effects have not been identified. We report that exposure to the dopamine releaser methamphetamine for 10 days elicits a long-lasting (>4 month) depression at corticostriatal terminals that is reversed by methamphetamine readministration. Both methamphetamine-induced chronic presynaptic depression and the drug's selective renormalization in drug-experienced animals are independent of corresponding long-term changes in synaptic dopamine release but are due to alterations in D1 dopamine and cholinergic receptor systems. These mechanisms might provide a synaptic basis that underlies addiction and habit learning and their long-term maintenance.
INTRODUCTION
Substance abuse is a chronic relapsing disorder in which drug reinstatement, even long after withdrawal, is thought to return the addict to a more stable, renormalized state (Ahmed and Koob, 2005; Koob, 1992; Redish, 2004) . How drugs produce long-lasting neuroplastic changes and how relapse provides compensation remain unknown, although a relationship between dopamine and corticostriatal synaptic activity is strongly implicated (Pessiglione et al., 2006; Vanderschuren and Kalivas, 2000) . Most addictive drugs acutely increase synaptic dopamine, and, in the case of the psychostimulants methamphetamine and amphetamine, do so via stimulation-independent, nonvesicular reverse transport through the dopamine transporter and by inhibiting reuptake (Sulzer et al., 2005) . The glutamatergic corticostriatal inputs are critical for the expression of behavioral and motoric responses (McFarland et al., 2003; Pessiglione et al., 2006; Pierce et al., 1996) , and animals repeatedly exposed to psychostimulants exhibit enhanced behavioral responses to drug reinstatement long after withdrawal (Bickerdike and Abercrombie, 1997; Brady et al., 2005) , with long-lasting reductions in basal extracellular glutamate and augmented glutamate release from corticostriatal inputs when the drugs are reinstated (McFarland et al., 2003; Pierce et al., 1996) . Very long-lasting presynaptic effects of dopamine on the corticostriatal inputs that could contribute to habit formation, addiction, or allostatic renormalization have not been reported, and we have taken advantage of new optical approaches to identify such changes.
RESULTS

Repeated Methamphetamine Induces Chronic Presynaptic Depression
To directly examine release from cortical terminals within the striatum ( Figure 1A ), we used the fluorescent tracer FM1-43 with multiphoton confocal microscopy in murine slice preparations. Stimulation of axons or cell bodies of projection neurons in layers 5-6 of the M1 motor cortex resulted in endocytosis of FM1-43 dye by recycling synaptic vesicles, revealing linear en passant arrays of fluorescent puncta characteristic of corticostriatal afferents (Bamford et al., 2004a (Bamford et al., , 2004b . Following dye loading, cortical restimulation resulted in exocytosis of FM1-43 dye from the terminals, decreasing in a manner approximating first-order kinetics characteristic of synaptic vesicle fusion (Figure 1B) . The kinetics of corticostriatal release were characterized (A) In this simplified striatal microcircuit, dopaminergic (DA) nigrostriatal fibers and cholinergic (ACh) interneurons modulate excitatory glutamatergic (GLU) corticostriatal projections on medium spiny neurons. Neurotransmitter release is modified by D1 and D2 DA receptors, M2 and M4 muscarinic receptors and a7*-and b2*-nicotinic receptors. (B) Multiphoton images of corticostriatal terminals obtained from the forelimb motor striatum, located 1.0-1.5 mm from the site of cortical stimulation. Images captured every 21.5 s reveal en passant arrays of corticostriatal terminals. Restimulation at t = 0 with 10 Hz pulses shows activity-dependent destaining of fluorescent puncta. Bar, 2 mm. (C) Amphetamine (Amph; 2 mg/kg i.p.)-elicited locomotor activity measured by ambulation summed over 90 min was determined in mice following repeated treatment with saline or methamphetamine (Meth) for 10 days. Repeated Meth produced a 1370%-1970% increase in Amph-elicited ambulation through 140 days of by the half-time (t 1/2 ), which is defined as the time required for terminal fluorescence to decay to half of its initial value.
We examined possible effects of repeated and intermittent methamphetamine administration on corticostriatal release. Because the effects of methamphetamine and amphetamine on striatal dopamine transmission are identical and are not discriminated by humans, we chose methamphetamine, which is more widely available to drug abusers, to use for in vivo administration in mice. Mice were treated with saline (controls) or methamphetamine once per day (20 mg/kg/day i.p.) for 10 consecutive days. This dose of methamphetamine may mimic plasma levels reached with self-administration during ''binges'' (Davidson et al., 2005) . Consistent with previous reports (Bickerdike and Abercrombie, 1997; Brady et al., 2005) , repeated treatment with methamphetamine induced an enhanced locomotor response to an amphetamine challenge (2 mg/kg i.p.), 1-140 days following treatment (Figures 1C and 1D; p < 0.001) . In these mice, repeated treatment with methamphetamine inhibited corticostriatal release , producing a highly prolonged state of corticostriatal depression in which the t 1/2 for release increased by 63%-90% during withdrawal (Figures 1H and 1I) , an effect we term chronic presynaptic depression (CPD). When half-times from individual terminals are presented relative to their standard deviation from the mean value, a straight line indicates a normally distributed (or single) population (Bamford et al., 2004b) . Repeated treatment with methamphetamine produced CPD by inhibiting release from all terminals, shifting the population to a distribution that remained mostly normal ( Figure 1I ).
Drug Reinstatement Reverses CPD
We then examined corticostriatal activity during psychostimulant readministration. In saline-treated controls, we found a 33% ± 12% depression of corticostriatal release in striatal slices prepared from mice challenged with a single dose of methamphetamine (20 mg/kg i.p., 30 min before death) in vivo (t 1/2 = 273 versus 203 s for controls; Figure 2A ; p < 0.05). In striking contrast to controls, a methamphetamine challenge in vivo 10 days following repeated methamphetamine exposure partially reversed CPD and potentiated release by 15% ± 2% (t 1/2 = 335 versus 285 s following challenge; Figure 2A ; p < 0.05), an effect we term paradoxical presynaptic potentiation (PPP). Amphetamine also induced PPP in mice treated with a lower repeated dose of methamphetamine (t 1/2 = 258 s; 10 mg/kg/day, 10 d; Figure 2B ) and did so by potentiating release from all terminals ( Figures 2C and 2D ).
Repeated Methamphetamine Abolishes Frequency-Dependent Inhibition
Our previous studies demonstrated that the magnitude of dopamine's inhibitory effect on corticostriatal activity is dependent on cortical stimulation frequency (Bamford et al., 2004b) . We observed the effect of frequency-dependence by unloading corticostriatal terminals at 1 Hz, 10 Hz, and 20 Hz before and after an amphetamine challenge (10 mM) in vitro. In saline-treated controls, amphetamine produced slower average unloading half-times at 10 Hz and 20 Hz (p < 0.001) but not at 1 Hz (p > 0.5; Figure 2E ). The magnitude of dopamine inhibition became progressively greater at higher corticostriatal stimulation frequencies, with a 6% inhibition for the mean t 1/2 values at 1 Hz (360/340 s), a 26% inhibition at 10 Hz (276/203 s), and a 36% inhibition at 20 Hz (275/175 s; p < 0.001 for interaction between amphetamine and stimulation frequency; F (2,1253) = 7.6; two-way ANOVA). As such, dopamine provides low-pass frequency filtering at corticostriatal terminals.
On withdrawal day 10 following repeated treatment with methamphetamine (20 mg/kg/day, 10 days), terminal release was depressed at 10 and 20 Hz (p < 0.001, repeated-measures ANOVA; Figure 2F ). Amphetamine in vitro accelerated release by 19% at 1 Hz (320/259 s) and 13% at 10 Hz (318/277 s) but had no effect at 20 Hz (276/276 s; p < 0.05 for interaction between amphetamine and stimulation frequency; F (2,1033) = 5.3; two-way ANOVA). Thus, in contrast to controls, where the greatest inhibitory effect of dopamine was seen at higher frequencies of stimulation, repeated treatment with methamphetamine produced the largest excitatory effect of dopamine at lower stimulation frequencies. Regardless of treatment or stimulation frequency, release closely approximated first-order kinetics (r 2 > 0.99; see Figure S1 available online).
The depression in release following repeated treatment with methamphetamine was not due to inadequate FM1-43 loading of the recycling synaptic vesicle pool, because loading stimulation frequencies of 1 Hz, 10 Hz, or 20 Hz (for 10 min) did not significantly affect unloading at 10 Hz either in saline-treated controls (t 1/2 = 221 s at 1 Hz, 203 s at 10 Hz, and 234 s at 20 Hz; data not shown; n = 82-391 puncta; p > 0.5, Mann-Whitney) or following repeated treatment with methamphetamine (t 1/2 = 300 s at 1 Hz, 318 s at 10 Hz, and 311 s at 20 Hz; data not shown; withdrawal (p < 0.001, t test with Bonferroni correction), significantly higher than in saline-treated mice challenged with saline (F (5,70) = 19; n = 8 mice per condition; p < 0.001). Repeated Meth also produced a 12%-219% increase in ambulations, compared with saline-treated mice also receiving Amph challenges (F (5,70) = 8.5; p < 0.001, repeated-measures ANOVA), although the difference between the two treatments narrowed after withdrawal day 20 (**p < 0.01, ***p < 0.001, ANOVA). All values are mean ± SE. (D) Amph-elicited locomotor activity 10 days following repeated Meth was higher and of longer duration, compared with responses from saline-treated mice challenged with Amph (F (17,238) = 9.1; n = 8 mice per condition; p < 0.001, repeated-measures ANOVA). 
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Corticostriatal Neuroplasticity n = 70-149 puncta; p > 0.1, Mann-Whitney). Furthermore, the number of active terminals in each slice was similar following each loading frequency (data not shown) and in both controls (38.1 ± 4 puncta) and withdrawal (31.5 ± 3 puncta; p = 0.12, ANOVA). The reduced fractional release of label during exocytosis ( Figure S2 ) could be due to a reduced probability of recycling synaptic vesicles that undergo exocytic fusion per stimulus, a reduced amount of FM1-43 released per exocytic event, or a combination of these mechanisms.
Dopamine Release Is Normal in Methamphetamine-Treated Mice
We explored whether these repeated methamphetamineinduced changes in corticostriatal release relied on long-term changes in dopamine transmission. PPP could not depend on changes in dopamine neuronal firing, because it was measured in the striatal slice from which dopamine cell bodies were absent, but repeated treatment with methamphetamine might produce long-lasting changes in dopamine terminals. To test this possibility, we examined electrically evoked dopamine release and reuptake using cyclic voltammetry in the same preparation. Mice were treated repeatedly with saline or methamphetamine (20 mg/kg/day, 10 days). On withdrawal days 1, 10, 30, and 140, striatal slice preparations containing presynaptic dopamine terminals were stimulated by a single electrical pulse, and the concentration and kinetics of dopamine release and reuptake were measured at subsecond resolution using fast-scan cyclic voltammetry, as described elsewhere (Zhang and Sulzer, 2004) . The only significant difference between saline-and methamphetamine-treated mice in response to a single pulse stimulus was on withdrawal day 1, when evoked dopamine release was depressed by 57% (2.3 mM dopamine versus 1.3 mM dopamine for controls and methamphetamine-treated mice, respectively; Figure S3A ; p < 0.01). There was no change in evoked dopamine release on withdrawal day 10, 30 and 140.
We further examined mice for alterations in synaptic shortterm presynaptic plasticity of the dopamine system. Dopamine release in response to train stimulus emulating phasic firing (4 pulses and 10 pulses at 100 Hz; Figure S3B ) was not altered on withdrawal day 1, 10, 30, or 140. The paired pulse ratio was not altered ( Figure S3C ). The time constants for the fast component (tf) and the slow component (ts) were 4.9 s and 16.7 s, respectively, for withdrawal mice, and were no different from those of controls (6.6 s and 16.5 s, respectively; p > 0.5).
To confirm that we were not examining effects due to neurotoxicity in this protocol, mice were also treated with methamphetamine (10 mg/kg i.p.) four times at 2 hr intervals, an established neurotoxic regimen. As expected on withdrawal day 10, dopamine release was reduced to 39% of control values by this neurotoxic regimen (0.84 mM dopamine versus 2.14 mM dopamine for controls and mice treated with methamphetamine four times, respectively; Figure S3D ; p < 0.001).
Finally, we examined amphetamine-induced dopamine release. The maximum level of striatal dopamine efflux reached $8 mM within 6-20 min ( Figure S3E ), similar to responses in untreated mice (Bamford et al., 2004b) , confirming that a psychostimulant challenge elicits typical maximum levels of dopamine release during withdrawal. Thus, although effects of methamphetamine on dopamine release apparently initiate CPD, the maintenance of CPD and PPP was apparently not due to changes in the ability of nigrostriatal terminals to release dopamine.
The lack of alterations in dopamine reuptake, short-term presynaptic plasticity, or the concentration of dopamine released by amphetamine detected during withdrawal indicates that repeated treatment with methamphetamine induces no long-lasting presynaptic alterations in dopamine neurotransmission. Thus, although increased dopamine transmission due to methamphetamine may have initiated long-term changes, the maintenance of CPD and the ability to produce PPP during withdrawal did not rely on an ongoing presynaptic alteration of dopamine transmission. The results further indicate that the protocols had no long-term neurotoxic effect on dopamine terminals.
Psychostimulants Filter Corticostriatal Release via D2 Receptors
Our previous results in the striatum of untreated mice showed that amphetamine inhibited exocytosis from less active corticostriatal terminals via activation of D2 receptors (D2Rs) (Bamford et al., 2004a (Bamford et al., , 2004b . In saline-treated mice, a methamphetamine challenge in vivo depressed corticostriatal exocytosis (t 1/2 = 272 s versus 201 s for controls; Figures 3A and 3B; p < 0.05). Similarly, acute amphetamine in vitro also decreased corticostriatal release (t 1/2 = 263 s versus 203 s for untreated slices; data not shown; n = 188-305 puncta; p < 0.001, Mann-Whitney).
In controls, the D2R antagonist sulpiride (10 mM) in vitro slightly potentiated terminal release (t 1/2 = 179 s versus 201 s without sulpiride; Figure 3B ; p > 0.5), indicating some tonic activation of inhibitory D2R. However, sulpiride completely blocked inhibition by a methamphetamine challenge (t 1/2 = 194 s versus 272 s for methamphetamine in vivo with and without sulpiride in vitro; Figures 3A and 3B and Figure S4 ; p < 0.001). A methamphetamine challenge in vivo created two reversible populations of terminals that diverged at À1 standard deviation below the mean, preferentially inhibiting slow-releasing terminals ($80%; Figure 3C) . Thus, a methamphetamine challenge in vivo or amphetamine in vitro produced a D2R-dependent filter with filtering applied preferentially to terminals with the lowest probability of release.
D2Rs Remain Inhibitory in Methamphetamine Withdrawal
We determined the effect of repeated treatment with methamphetamine on D2R-mediated corticostriatal filtering. On withdrawal day 10 following repeated treatment with methamphetamine, a methamphetamine challenge in vivo produced PPP (t 1/2 = 335 s versus 285 s following the challenge; Figures 3D and 3E; p < 0.05). Similarly, an amphetamine challenge in vitro also potentiated release on withdrawal days 1-140 ( Figures 3F  and 3G ).
On withdrawal day 10, sulpiride slightly potentiated terminal release (t 1/2 = 299 s versus 335 s without sulpiride; Figure 3E ; p > 0.3). However, it enhanced, rather than reversed PPP following a methamphetamine challenge in vivo, increasing corticostriatal release to control values (t 1/2 = 227 s; Figures 3D and 3E; p > 0.5 versus controls). Sulpiride also enhanced PPP due to amphetamine in vitro, potentiating release to control values (t 1/2 = 203 s; p > 0.5) on withdrawal days 1-140 (Figures 3F and 3G and Figure S4 ). Thus, in animals repeatedly treated with methamphetamine, a methamphetamine challenge in vivo or an amphetamine challenge in vitro induced PPP to partially normalize corticostriatal release, and PPP completely reversed CPD once D2R inhibition was blocked. The results demonstrated that PPP was not due to an activation of D2Rs, because these receptors continued to be inhibitory during withdrawal.
CPD Is Reversed through D1 Receptor Actions
An alternate possibility is that psychostimulant activation of D1 receptors (D1Rs) might induce PPP. As in our previous studies (Bamford et al., 2004a (Bamford et al., , 2004b , the D1R agonist SKF38393 (10 mM; t 1/2 = 186 s versus 203 s without SKF38393; p > 0.5) or antagonist SCH23390 (10 mM; t 1/2 = 193 s; p > 0.5) had little effect on corticostriatal release in saline-treated controls (Figures 4A and 4B) . Furthermore, SCH23390 had no effect on corticostriatal release even when dopamine was released by amphetamine (t 1/2 = 262 s versus 262 s without SCH23390; Figure 4B ; p > 0.5). Thus, D1R stimulation did not significantly affect corticostriatal activity under control conditions.
In marked contrast, on withdrawal day 10 following repeated treatment with methamphetamine, the D1R agonist SKF38393 strongly potentiated release and partially reversed CPD (t 1/2 = 233 s versus 318 s without SKF38393; Figures 4C and 4D; p < 0.001) by renormalizing the activity of the faster-releasing terminals ( Figure 4E ), whereas the D1R antagonist SCH23390 had no effect (t 1/2 = 313 s; Figures 4C-4E; p > 0.5). As expected, SCH23390 largely blocked the excitatory response produced with SKF38393 (t 1/2 = 289 s for SCH23390 and SKF38393; data not shown; n = 113 puncta; p > 0.5 versus SCH23390 alone, Mann-Whitney). The combination of sulpiride and SKF38393 further enhanced release and fully reversed CPD (t 1/2 = 202 s; p > 0.5 versus untreated sections) by additionally accelerating exocytosis from slower terminals ( Figure 4E ). Combined SKF38393 and sulpiride also reversed CPD in mice treated with lower doses of methamphetamine (10 mg/kg/day; t 1/2 = 225 s versus 307 s without SKF38393 and sulpiride; data not shown; n = 250 puncta; p < 0.001, Mann-Whitney). Amphetamine-induced D1R activation was responsible for PPP, because PPP was reversed by SCH23390 (t 1/2 = 356 s; p < 0.001) even when sulpiride, which might be expected to enhance release by blocking any lingering D2R-mediated inhibition, was included with SCH23390 (t 1/2 = 333 s; Figure 4D ; p < 0.01). The excitatory effects of SKF38393 on amphetamine-induced PPP were not additive (t 1/2 = 265 s; p = 0.04 versus SKF38393 alone), and were identical to amphetamine alone (t 1/2 = 263 s; Figure 4D ; p > 0.5). Together, the results show that, although D1Rs have no effect on corticostriatal release in controls, their actions become excitatory following repeated treatment with methamphetamine. Amphetamine has less excitatory effect than does the D1R agonist, because dopamine would also inhibit release through presynaptic D2R actions.
Locomotor Activity Is Dependent on a New D1R Effect Because a psychostimulant challenge in withdrawal would produce striatal excitation and allow excessive locomotor responses through a D1R-mediated pathway, blockade of this receptor might prevent these sensitized behavioral responses. Consistent with previous reports (Kuribara, 1995) , we found that increasing (A) Compared to untreated sections (Veh), the D1R agonist SKF38393 (SKF; n = 169 puncta) and antagonist SCH23390 (SCH; n = 386 puncta) in vitro had no effect on release in controls following repeated saline. (B) Distribution of mean t 1/2 of release for destaining curves shown in panel A with additional experimental groups from controls. Compared to untreated sections (Veh; n = 188 puncta), Amph (n = 305 puncta) inhibited release, but the D1R agonist SKF (n = 169 puncta) and antagonist SCH (n = 386 puncta) had no effect. In the presence of Amph, SCH had no effect with (n = 116 puncta) or without SULP (n = 151 puncta; ***p < 0.001 versus Veh, Mann-Whitney). (C) Ten days following repeated Meth (withdrawal), SKF accelerated release, whereas SCH had no effect. (D) Distribution of mean t 1/2 of release for destaining curves shown in panel C with additional experimental groups from withdrawal. Amph in vitro (n = 128 puncta) boosted release to elicit PPP. SKF (n = 247 puncta) increased release to a greater extent than Amph, whereas SCH (n = 266 puncta) had no effect. SCH (n = 212 puncta) blocked the potentiating effect of Amph. SCH in combination with Sulp (n = 161 puncta) also blocked accelerated release by Amph, whereas SKF (n = 168 puncta) had little effect on PPP produced by Amph (*p < 0.05, **p < 0.01; ***p < 0.001 versus Veh; n = 149 puncta; Mann-Whitney).
(E) Individual terminal responses to D1 and D2R manipulation in withdrawal. (F) Mice were treated with Meth (20 mg/kg/day i.p.) for 10 days. An Amph challenge (2 mg/kg i.p.) on withdrawal day 10 induced sensitized locomotor ambulations summed over 90 min. The D1R antagonist SCH inhibited this locomotor response (*p < 0.001; n = 8 mice per treatment group) with a significant linear trend over dose levels (r 2 = 0.97).
(G) Interval locomotor responses for treatment groups in panel F.
(H) Additional mice were treated with saline for 10 days. Ten days later, these mice were treated with the D1R antagonist SCH and were challenged with saline. There were small variations in locomotor activity but at the doses used, SCH had no effect on locomotor activity (p = 0.48; n = 8 mice per treatment group; r 2 = 0.01).
Values are mean ± SE.
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Corticostriatal Neuroplasticity concentrations of the D1R antagonist SCH23390 (10-40 mg/kg s.c.; 30 min before an amphetamine challenge) produced a dose-dependent reduction in locomotor responses to an amphetamine challenge (2 mg/kg) on withdrawal day 10 ( Figures  4F and 4G ; p < 0.001), but had no effect on saline-treated controls ( Figure 4H ; p > 0.5). Thus, both augmentation of corticostriatal release and enhanced locomotion are dependent on a new D1R effect that is seen only following repeated exposure to methamphetamine.
CPD and PPP Are Mediated through Acetylcholine Receptors Although D1R activation reversed CPD and mediated PPP, the results did not reveal where the responsible D1R was acting. We suspected that CPD and PPP might be mediated indirectly through cholinergic tonically active interneurons (TANs) that represent a small fraction of striatal neurons but provide the majority of striatal acetylcholine (ACh) transmission. Amphetamine exerts multiple state-dependent effects on striatal extracellular ACh efflux (DeBoer and Abercrombie, 1996) . TANs possess D1-and D2-like receptors (DeBoer and Abercrombie, 1996; Yan et al., 1997; Le Moine et al, 1991) , and their activity mediates corticostriatal responses, including dopamine-dependent corticostriatal long-term depression (LTD) (Wang et al., 2006) via b2* and a7* nicotinic receptors (nAChRs) on TANs (Azam et al., 2003) , a7* receptors found on corticostriatal terminals (Marchi et al., 2002; Pakkanen et al., 2005; Wang and Sun, 2005 ) that exert tonic excitation, and M2 muscarinic ACh receptors (mAChRs) that are inhibitory (Calabresi et al., 2000; Hersch et al., 1994; Volpicelli-Daley et al., 2003; Zhang et al., 2002) . nAChRs are rapidly desensitized at high agonist levels, in which case the agonists prevent tonic excitation and thus inhibit release (Wooltorton et al., 2003) . In slices from saline-treated mice, bath application of ACh (1-100 mM) potently inhibited release ( Figure 5A ), consistent with either mAChR-mediated depression and/or a desensitization of tonically activated nAChR (Quick and Lester, 2002) . We determined that tonic ACh in controls was excitatory because vesamicol (5 mM), a potent inhibitor of vesicular ACh uptake, inhibited corticostriatal release in controls (t 1/2 = 298 s; n = 135 puncta; data not shown; p < 0.001, Mann-Whitney) to a degree similar to CPD (318 s; p > 0.5, Mann-Whitney).
These cholinergic receptor responses were markedly altered by repeated treatment with methamphetamine. Low concentrations of bath-applied ACh reversed CPD in withdrawal and accelerated release beyond control half-times (t 1/2 = 178 s at 10 mM ACh versus 203 s for controls; Figures 5A and 5B; p < 0.05), suggesting a sensitized excitatory response to exogenous ACh. ACh also accelerated release on withdrawal day 10 following a lower daily dose of methamphetamine (10 mg/kg/day, 10 d; Figure 5A ). Higher concentrations of ACh (>50 mM), which were expected to desensitize nAChR (Quick and Lester, 2002) , inhibited release ( Figure 5A ). Although ACh depletion by vesamicol inhibited release in controls, it had no effect on CPD (t 1/2 = 332 s; n = 126 puncta; Figure 5B we examined the effects of repeated treatment with methamphetamine on striatal tissue ACh content. In saline-treated mice, a methamphetamine challenge (20 mg/kg i.p., 30 min before death) decreased ACh content by 35% (p < 0.05, t test), whereas repeated treatment with methamphetamine decreased striatal ACh during withdrawal by 46%-76% (p < 0.01), an effect partially reversed following methamphetamine reinstatement ( Figure 5C ; p < 0.05, t test).
Loss of Nicotinic Excitation Results in CPD
This methamphetamine-induced reduction in ACh would likely perturb both nAChR and mAChR responses. In saline-treated controls, the classic nAChR agonist, nicotine (5-500 nM), inhibited corticostriatal release ( Figure 5D ), consistent with the compound's ability to rapidly desensitize b2*-nAChR (Quick and Lester, 2002; Wooltorton et al., 2003) and prevent ongoing corticostriatal excitation by tonic ACh. Corticostriatal release is dependent on tonic excitation by nAChR, because the nAChR antagonist mecamylamine reduced release (10 mM; t 1/2 = 295 s versus 203 s for controls; n = 168 puncta; data not shown; p < 0.001, Mann-Whitney). Tonic nAChR excitation appeared to be due to actions at a7*-like nAChRs, because the a7* antagonist methyllycaconitine (20 nM) inhibited corticostriatal release (t 1/2 = 278 s; n = 186 puncta; p < 0.001, Mann-Whitney). Likewise, choline (10 mM), an agonist that desensitizes a7*-nAChR (Turner, 2004) , inhibited release in slices from saline-treated controls (t 1/2 = 435 s versus 203 s for controls; n = 66 puncta; data not shown; p < 0.001, Mann-Whitney). In addition, the b2*-nAChR antagonist dihydro-b-erythroidine (DHbE; 300 nM) also reduced release (t 1/2 = 279 s; data not shown; n = 97 puncta; p < 0.001, Mann-Whitney).
In contrast to controls, low concentrations of nicotine (5 nM) 10 days following repeated treatment with methamphetamine reversed CPD (t 1/2 = 200 s versus 203 s for controls; Figures 5D and 5E; p > 0.5, Mann-Whitney) via a strong excitatory response that normalized release for all but the $20% slowest terminals ( Figure 5F ). As expected, this effect was blocked by the b2*-nAChR antagonist DHbE (t 1/2 = 317 s; n = 122 puncta; data not shown; p > 0.5, Mann-Whitney). Similar to bath-applied ACh, this potentiation was lost at higher nicotine levels ( Figures  5D and 5F ), consistent with b2*-nAChR desensitization (Wooltorton et al., 2003) . Tonic nAChR excitation was not observed in methamphetamine withdrawal, because the nicotinic receptor blocker mecamylamine (t 1/2 = 295 s versus 318 s with and without mecamylamine; Figures 5E and 5G; p > 0.5), the desensitizing a7*-nAChR agonist choline (t 1/2 = 326 s; n = 127 puncta; data not shown; p > 0.5, Mann-Whitney), and the b2*-nAChR antagonist DHbE (t 1/2 = 302 s; n = 99 puncta; data not shown; p > 0.5, Mann-Whitney) no longer inhibited release as they did in controls. AChR-induced PPP occurred downstream of D1R action, because mecamylamine blocked PPP elicited by the D1 agonist SKF38393 (t 1/2 = 233 s for SKF38393 versus 290 s for SKF38393 with mecamylamine; Figure 5G ; p < 0.001) and by amphetamine (t 1/2 = 277 s for amphetamine versus 352 s for amphetamine with mecamylamine; Figures 5G and 5H; p < 0.001) as did desensitizing nicotine levels (50 nM; t 1/2 = 330 s for amphetamine and nicotine; Figure 5H ; p < 0.001).
Muscarinic Receptors Become Sensitized during Withdrawal
Next, we examined the effect of repeated treatment with methamphetamine on mAChR responses. In slices from salinetreated mice, the mAChR agonist muscarine ( Figure 6A ) inhibited release, whereas the antagonist, atropine (1-20 mM) had no effect ( Figure 6B ), indicating that tonic ACh did not inhibit corticostriatal activity via mAChR. Thus, in controls, tonic ACh exerted no inhibition at mAChR while providing ongoing excitation at nAChRs.
Muscarine continued to be inhibitory in withdrawal ( Figure 6A ) but reached a maximum effect at a lower concentration (78% of maximum inhibition at 0.1 mM in controls versus 98% of maximum inhibition in withdrawal; Figure 6A ; p < 0.001), consistent with hypersensitive mAChR responses. However, atropine reversed CPD ( Figures 6B and 6C ) at all varicosities except the slowest $20% of the population ( Figure 6D ), a state nearly identical to that following the D1 agonist, SKF38393 (Figure 4E ), or low concentrations of nicotine ( Figure 5F ) or ACh (10 mM; data not shown).
Together, these data indicate that during withdrawal, low tonic ACh levels were associated with sensitized responses by both nAChR and mAChR. The sensitized mAChR response contributed to CPD and occurred downstream of D1R action, as atropine (1 mM) reversed CPD in the presence of either SKF38393 or SCH23390 ( Figure 6E ). The mAChR response was upstream of nAChR excitation, as both desensitizing concentrations of nicotine (50 nM; t 1/2 = 310 s versus 196 s for atropine [10 mM] alone; n = 131 puncta; p < 0.001, Mann-Whitney) and mecamylamine (t 1/2 = 324 s; data not shown; n = 101 puncta; p < 0.001, Mann-Whitney) prevented atropine potentiation during withdrawal. mAChR activation, however, played no role in PPP, because atropine did not block amphetamine excitation in with- Thus, withdrawal mice selectively exhibited two, long-lasting forms of methamphetamine-induced presynaptic corticostriatal plasticity. CPD is due to a tonic inhibition mediated by reduced tonic nAChR excitation combined with a tonic mAChR inhibition, whereas PPP is due to psychostimulant-induced D1 activation that boosts corticostriatal release by activating nAChRs. These results are consistent with evidence that both nAChR and mAChR sensitivity are strongly regulated by ACh input, with low ACh levels generally promoting supersensitivity (Overstreet and Djuric, 2001 ). This balance between opposing ACh effects is altered by methamphetamine-induced sensitized nAChR and mAChR responses. As was observed following simulation of PPP by low nicotine levels, withdrawal mice are very sensitive to nAChR excitation, although higher nicotine or ACh levels cause desensitization and eliminate PPP.
CPD and PPP in Postsynaptic Medium Spiny Neurons
We expected that changes in glutamate release from cortical afferents during CPD and PPP would be reflected in postsynaptic medium spiny neurons. Mice were treated with saline (n = 8) or methamphetamine (20 mg/kg/day i.p.; n = 9) for 10 days. Recordings from medium spiny neurons in voltage-clamp mode (n = 28 from saline-treated mice and n = 31 from methamphetaminetreated mice), obtained 10 days after the last injection, revealed no differences in passive membrane properties between groups (membrane capacitance, 97.5 ± 3.3 and 93.8 ± 2.4 pF; input resistance, 87.0 ± 4.4 and 92.9 ± 8.4 MU; time constant, 1.5 ± 0.1 and 1.6 ± 0.1 ms, respectively). The average frequency of spontaneous excitatory postsynaptic currents (sEPSCs; Figure 7A [left] and Figure 7B ) was higher in cells from saline-treated mice, compared with methamphetamine-treated mice (1.17 ± 0.11 Hz and 0.94 ± 0.07 Hz; p = 0.036), providing electrophysiological evidence supporting CPD. In a subset of cells (n = 6 from saline-treated mice and n = 7 from methamphetamine-treated mice) tetrodotoxin (TTX; 1 mM) was used to isolate miniature (m) EPSCs ( Figure 7A [right] and Figure 7C ). In this group, the frequency of sEPSCs also was significantly higher in saline-treated mice than in methamphetamine-treated mice (p = 0.033). After administration of TTX, the average frequency of mEPSCs ( Figure 7C ) remained significantly higher (p = 0.047) in cells from control mice (1.2 ± 0.2 Hz), compared with methamphetamine-treated mice (0.7 ± 0.1 Hz). Differences in frequency were more dramatic after administration of TTX, indicating that in the absence of this blocker, cortical pyramidal neuron firing may be increased in methamphetamine-treated mice, compared with controls, possibly as a compensatory mechanism. In contrast, average mEPSCs amplitudes were similar between groups (10.4 ± 0.9 pA in cells from saline-treated mice and 8.8 ± 0.8 pA in cells from methamphetamine-treated mice). This finding indicates that in methamphetamine-treated mice there was a depression of synaptic transmission in the corticostriatal pathway and that this depression was independent of action potentials because it persisted in the presence of TTX. Evidence for reduced glutamate transmission was also obtained from evoked EPSCs. The current required to evoke EPSCs ( Figure 7D ) was significantly higher in cells from methamphetamine-treated mice (0.46 ± 0.05 mA) than in cells from saline-treated mice (0.32 ± 0.04 mA) (p = 0.021). The average evoked EPSC amplitude was determined at threshold intensity +0.1 mA in cells from saline-and methamphetamine-treated mice. At 0.42 mA, the average EPSC amplitude in control cells was À104.3 ± 11.7 pA (n = 18), and at 0.56 mA the amplitude in methamphetamine-treated cells was À93.3 ± 10.8 pA (n = 23). Thus, to obtain comparable responses, higher intensities need to be used in methamphetamine-treated mice than in control mice, providing further evidence of CPD.
To determine whether PPP also could be demonstrated in postsynaptic neurons, amphetamine (10 mM) was bath applied to examine its effects on sEPSCs. Amphetamine produced a small reduction (3%) in average frequency of sEPSCs in cells (n = 5) from saline-treated mice, whereas it significantly increased the frequency (34%) in cells (n = 8) from methamphetaminetreated mice (p = 0.02, Figure S5A ). Furthermore, PPP was likely mediated by D1Rs because bath application of the D1R agonist SKF38393 (10 mM) produced no significant change (7% increase) in the frequency of sEPSCs in cells (n = 6) from saline-treated mice but significantly increased (34% increase) the frequency in cells (n = 7) from methamphetamine-treated mice (p = 0.015; Figure S5B ). As expected, the D1R antagonist SCH23390 (1 mM) had no effect on the frequency of sEPSCs (n = 5 cells from saline-treated mice and n = 6 cells from methamphetamine-treated mice; Figure S5C ). In contrast, bath application of the D2R antagonist sulpiride (10 mM) significantly increased the frequency of sEPSCs in both groups (58% in saline-treated mice and 28% in methamphetamine-treated mice; p = 0.007 and p = 0.015, respectively; Figure S5D ). However, the addition of amphetamine produced a further increase (12%) in cells from methamphetamine-treated mice, whereas it reduced (10%) the frequency in cells from control mice (data not shown). Overall, these electrophysiological data support the optical recordings of presynaptic release and demonstrate that CPD and PPP produce alterations in the excitation of postsynaptic neurons.
DISCUSSION
We report that repeated methamphetamine treatment causes long-lasting synaptic changes in the corticostriatal pathway that were previously suggested by theoretical models to underlie drug dependence. The CPD induced by the drug occurs at corticostriatal terminals and is independent of long-term changes in striatal dopamine terminals. PPP by drug reinstatement occurs both in vivo and in vitro exclusively in animals that have undergone withdrawal and acts to partially renormalize synaptic activity. Although the precise mechanisms underlying CPD and PPP require elucidation, the data indicate that D1 dopamine and cholinergic responses are required for these long-term adaptations to drug administration.
CPD was indicated by a decreased rate of exocytosis of the recycling synaptic vesicle pool in motor corticostriatal terminals in mice repeatedly exposed to methamphetamine, together with a reduction in spontaneous and mEPSCs, as well as by the increased threshold required to evoke EPSCs in methamphetamine-treated mice. The optical recordings indicate that the changes were presynaptic, whereas the electrophysiological results confirm a presynaptic locus, because they occurred in the presence of TTX, and as the amplitude of mEPSCs was not different in cells from saline-or methamphetamine-treated mice. PPP was clearly observed by the increased rate of exocytosis of the recycling vesicle pool with psychostimulant reinstatement, which occurred only in mice previously exposed to repeated treatment with methamphetamine, as well as by the paradoxical increase in sEPSCs after amphetamine and a D1R agonist, an effect never observed in control conditions.
How might dopamine release during repeated treatment with methamphetamine exert long-lasting changes in ACh transmission and initiate CPD and PPP without a concomitant long-lasting change in dopamine release? Opposing D1R-excitatory and D2R-inhibitory mechanisms regulate cholinergic efflux in the striatum (Bertorelli and Consolo, 1990; DeBoer and Abercrombie, 1996) , because TANs possess D2Rs that inhibit ACh release (Yan et al., 1997) and D1Rs that enhance ACh efflux (Figure 8 ) (Abercrombie and DeBoer, 1997; DeBoer and Abercrombie, 1996; Le Moine et al., 1991; Yan et al., 1997) . Under control (A) The simplified striatal circuit is composed of MSNs that receive excitatory GLU corticostriatal projections, modulatory DA nigrostriatal fibers, and tonically active ACh-releasing interneurons (TANs). ACh modulates GLU release (Malenka and Kocsis, 1988) through excitatory a7*-nicotinic (NIC) (Marchi et al., 2002; Pakkanen et al., 2005) and inhibitory M2 mAChRs (Calabresi et al., 2000) located on corticostriatal terminals (Hersch et al., 1994) and regulates its own release through M4 muscarinic (Zhang et al., 2002) and both a7*-NIC and b2*-NIC autoreceptors (Azam et al., 2003) . (B) Under control conditions, DA released by a psychostimulant inhibits GLU release from a subset of cortical terminals via D2R (Bamford et al., 2004b) . Although TANs possess both inhibitory D2R (Yan et al., 1997) and excitatory D1R (Le Moine et al., 1991; Yan et al., 1997) , D2R responses predominate so that DA reduces ACh efflux from striatal cholinergic interneurons (DeBoer and Abercrombie, 1996) . (C) Following repeated Meth, a reduction in ACh availability sensitizes muscarinic and nicotinic receptors. Enhanced muscarinic inhibition and reduced nicotinic excitation promotes CPD. (D) During withdrawal, DA released by a psychostimulant challenge induces PPP. DA increases ACh efflux (Bickerdike and Abercrombie, 1997) through TAN D1R responses (Berlanga et al., 2003) to excite GLU release through a7*-nAChRs.
conditions, responses to dopamine favor D2R-mediated inhibition of ACh efflux (DeBoer and Abercrombie, 1996) . ACh accelerates corticostriatal release through a7*-nAChR (Marchi et al., 2002; Pakkanen et al., 2005; Wang and Sun, 2005) and inhibits corticostriatal release through M2 mAChRs (Calabresi et al., 2000; Hersch et al., 1994) , with mAChR responses submissive to alterations in nAChR sensitivity (Wang and Sun, 2005) . Our data are consistent with dominant regulation by tonic nAChR in control mice, because mAChR blockade by atropine did not affect release, whereas nAChR blockade with mecamylamine, ACh depletion with vesamicol, and desensitization of nAChR by nicotine and choline all were inhibitory. The lack of tonic ACh influence via mAChR on control corticostriatal activity is in agreement with previous literature (Malenka and Kocsis, 1988) . It may be that the tonic levels of ACh are normally too low to desensitize nAChR, but that when higher levels are reached, there is an allosteric regulation of mAChRs which provides enhanced affinity to ACh (Wang and Sun, 2005) .
The situation in drug-naive animals is markedly altered in withdrawal, possibly because repeated treatment with methamphetamine reduces ACh levels, limiting corticostriatal nAChR excitation and sensitizing both mACh and nACh receptors (Siegal et al., 2004) . Persistent dopamine release during repeated treatment with methamphetamine may additionally uncouple D1R/D2R synergisms (Hu and White, 1994; Kashihara et al., 1999) on TAN neurons, favoring D1R excitation (Berlanga et al., 2003) so that methamphetamine challenge during withdrawal activates TAN D1R and enhances ACh release (Bickerdike and Abercrombie, 1997 ) to activate PPP. The dependence of PPP on D1R and nAChR activation could contribute to the ability of D1 antagonists to block sensitized locomotor responses or drug selfadministration in rodents (Ciccocioppo et al., 2001) .
Our data do not directly indicate the locus of AChRs responsible for methamphetamine-induced corticostriatal plasticity. The nAChRs that mediate PPP may be on corticostriatal terminals (Marchi et al., 2002; Pakkanen et al., 2005; Wang and Sun, 2005) or TANs (Azam et al., 2003) . Likewise, the mAChRs responsible for CPD may also be at presynaptic sites (Calabresi et al., 2000; Hersch et al., 1994) , on TANs (Zhang et al., 2002) , or elsewhere. The mAChR may be an inhibitory TAN autoreceptor (Zhang et al., 2002) , since nAChR stimulation is required to reverse CPD.
An advantage of presynaptic optical measurements is that variability between individual presynaptic terminals can be analyzed. Our FM1-43 loading protocol is fairly extensive (10 min, 10 Hz), and saturates those terminals capable of dye uptake (i.e., additional stimulation results in no additional labeled terminals). Because CPD in withdrawal is reversed by pharmacological treatment following loading, it is not due to a decreased number of active terminals or a smaller pool of recycling synaptic vesicles but rather a decreased probability of fusion of recycling vesicles. A decreased probability of synaptic vesicle fusion is consistent with the decreased mEPSC frequency in the presence of TTX following withdrawal.
The distribution of individual cortical terminal half-times in controls demonstrated that stimulation of D2R during periods of high cortical activity depresses release from the majority of cortical terminals, preferentially inhibiting the activity of the terminals with the lowest probability of release, an effect that occurs in the dynamic and kinetic range of dopamine input associated with both salient behavioral stimuli and psychostimulants (Bamford et al., 2004b) . Thus, dopamine release associated with salience during learning would reinforce specific corticostriatal connections by filtering out less-effective cortical terminal inputs (Bamford et al., 2004b) . Repeated treatment with methamphetamine would disrupt this filtering mechanism by inducing CPD. The induction of CPD is dopamine dependent, but CPD continues to be expressed even when dopamine release returns to normal. This indicates that long-lasting plasticity, once initiated, does not require a corresponding long-lasting change in the dopamine system. Subsequent psychostimulant readministration, however, would enhance striatal ACh release by activating D1R, and thus induce PPP by accelerating exocytosis from corticostriatal terminals. PPP provides a mechanism by which drug readministration renormalizes synaptic function following withdrawal, a feature long suggested to be required for addiction, and may favor the conversion of LTD to LTP (Nishioku et al., 1999) . Because striatal LTD and LTP are implicated in memory for habitual behaviors (Jog et al., 1999; Packard and Knowlton, 2002) , these findings support the idea that the striatum is likely to be the site for storage of information related to locomotor sensitization and drug addiction (Gerdeman et al., 2003; Koob, 1992) .
EXPERIMENTAL PROCEDURES
Animals and Statistics
Experimental procedures were performed in accordance with the USPHS Guide for Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee at the University of Washington, Columbia University, and UCLA. C57BL/6 mice aged 12-16 weeks were obtained from Jackson Labs (Bar Harbor, ME). Mice were treated with methamphetamine (10 or 20 mg/kg/day, i.p.) or with an equal volume of 0.9% saline by daily injection for 10 days. In some studies, mice were challenged by a single dose of methamphetamine (20 mg/kg, i.p.) or amphetamine (2 mg/kg i.p.) in vivo. Mice were anesthetized with Nembutal or ketamine/xylazine before death. Mice for electrochemical recordings were treated in University of Washington and shipped to Columbia University. Some mice were treated at Columbia University to exclude possible effects of stress. For in vivo studies, mice were sacrificed 30 min following administration of methamphetamine, when dopamine efflux is expected to reach peak concentrations (McFarland et al., 2003) . To ensure equilibrium, sections were exposed to pharmacological agents for 10 min before stimulation-mediated unloading. All drugs were obtained from Sigma (St. Louis, MO).
Values given in the text and in the figures are mean ± SE. To establish differences in FM1-43 release between groups of mice exposed to saline or methamphetamine, release half-times from each mouse were averaged, and significance was determined by use of the t test with Bonferroni correction (n = number of mice). Differences between nonparametric release half-times (t 1/2 ) following receptor perturbation were determined using the Mann-Whitney test (n = number of puncta). Comparisons between groups of puncta represent data collected from 4-6 mice, and comparisons between groups of mice represent the average of 149-439 puncta from 6-12 slices per mouse. Differences were considered significant at levels of p < 0.05. Changes in terminal subpopulations were determined graphically using normal probability plots by comparing individual terminal release to normally distributed data.
Behavioral Protocol
Locomotor responses were determined using animal activity monitor cages, as described in the Supplemental Data.
Optical Imaging with FM1-43
Optical recordings of cortical afferents in the motor striatum were obtained as described elsewhere (Bamford et al., 2004a) and are further detailed in the Supplemental Data.
Electrochemical Recordings with Cyclic Voltammetry
Striatal dopamine release was studied in 3-5 pairs of methamphetaminetreated mice and their saline-treated controls for each withdrawal day (i.e., day 1, day 10, day 30, and day 140), using fast-scan cyclic voltammetry. Electrochemical recordings and electrical stimulation were adapted from previous studies (Schmitz et al., 2001) , and the procedures are described further in the Supplemental Data.
Detection of Striatal ACh Concentrations
ACh tissue concentrations were determined by high-performance liquid chromatography, based on a reaction with acetylcholinesterase and choline oxidase (Vanderbilt Kennedy Center, Vanderbilt, TN), according to previous publications (Bertrand et al., 1994; Damsma et al., 1985) , as further described in the Supplemental Data.
Electrophysiology
Electrophysiological recordings in medium spiny neurons were obtained as described elsewhere (Cepeda et al., 1998) and are further detailed in the Supplemental Data.
SUPPLEMENTAL DATA
The Supplemental Data for this article can be found online at http://www. neuron.org/cgi/content/full/58/1/89/DC1/.
